Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting.
The hu14.18-IL2 (EMD 273063) IC, consisting of a GD(2)-specific mAb genetically engineered to two molecules of IL-2, is in clinical trials for treatment of GD(2)-expressing tumors. Anti-tumor activity of IC in vivo and in vitro involves NK cells. We studied the kinetics of retention of IC on the surface of human CD25(+)CD16(-) NK cell lines (NKL and RL12) and GD(2)(+) M21 melanoma after IC binding to the cells via IL-2R and GD(2), respectively. For NK cells, ∼ 50% of IC was internalized by 3 h and ∼ 90% by 24 h of cell culture. The decrease of surface IC levels on NK cells correlated with the loss of their ability to bind to tumor cells and mediate antibody-dependent cellular cytotoxicity in vitro. Unlike NK cells, M21 cells retained ∼ 70% of IC on the surface following 24 h of culture and maintained the ability to become conjugated and lysed by NK cells. When NKL cells were injected into M21-bearing SCID mice, IT delivery of IC augmented NK cell migration into the tumor. These studies demonstrate that once IC binds to the tumor, it is present on the tumor surface for a prolonged time, inducing the recruitment of NK cells to the tumor site, followed by tumor cell killing.
UW Carbone Cancer Center, 4159 MACC Fund UW Childhood Cancer Research Wing, WIMR, 1111 Highland Ave., Madison, WI 53705-2275, USA.
Ilia N
IN
Buhtoiarov
Zane C
ZC
Neal
Jacek
J
Gan
Tatiana N
TN
Buhtoiarova
Manish S
MS
Patankar
Jennifer A A
JA
Gubbels
Jacquelyn A
JA
Hank
Brett
B
Yamane
Alexander L
AL
Rakhmilevich
Ralph A
RA
Reisfeld
Stephen D
SD
Gillies
Paul M
PM
Sondel
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D000920:Antibody-Dependent Cell Cytotoxicity; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D008545:Melanoma / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D051379:Mice; D016513:Mice, SCID; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D007376:Interleukin-2; C493743:lorukafusp alfa
Cancer Res. 2001 Feb 15;61(4):1500-7
11245457
J Exp Med. 2005 Oct 3;202(7):941-53
16203865
Clin Cancer Res. 2008 Aug 1;14(15):4951-60
18676770
Ann Clin Lab Sci. 1978 Jan-Feb;8(1):50-6
623430
Clin Cancer Res. 1996 Dec;2(12):1951-9
9816154
Cancer. 1992 Aug 1;70(3):633-8
1623478
J Biol Chem. 1986 Nov 25;261(33):15450-4
3096988
Pigment Cell Res. 1992;Suppl 2:109-12
1409412
Clin Cancer Res. 2006 Mar 15;12(6):1750-9
16551859
J Clin Oncol. 2009 Jan 1;27(1):85-91
19047298
Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1428-32
1741398
J Clin Oncol. 2004 Nov 15;22(22):4463-73
15483010
Science. 1989 May 5;244(4904):551-6
2785715
Exp Toxicol Pathol. 2000 Aug;52(4):277-85
10987178
Cancer Res. 1990 Sep 1;50(17):5234-9
2386933
Eur J Immunol. 1986 Nov;16(11):1461-3
3096748
Clin Cancer Res. 2004 Jul 15;10(14):4839-47
15269160
Cancer Res. 2001 Jun 1;61(11):4474-82
11389078
Bioconjug Chem. 2003 Nov-Dec;14(6):1115-21
14624624
Cancer Res. 1986 Oct;46(10):5112-8
3019521
Hum Pathol. 2004 Jan;35(1):122-8
14745734
J Clin Oncol. 2010 Nov 20;28(33):4969-75
20921469
Semin Cancer Biol. 1991 Dec;2(6):401-9
1810468
J Immunol. 2000 Sep 1;165(5):2556-62
10946282
Proc Natl Acad Sci U S A. 1985 Feb;82(3):864-8
2983318
Methods Mol Med. 2003;85:123-31
12710203
Exp Hematol. 1996 Feb;24(3):406-15
8599969
Clin Cancer Res. 2008 Oct 15;14(20):6515-24
18927291
Cancer Res. 1987 Jan 1;47(1):183-7
3024814
Cell. 1989 Dec 1;59(5):837-45
2590941
J Immunother. 2004 May-Jun;27(3):211-9
15076138
J Exp Med. 1986 Mar 1;163(3):550-62
3005464
Cancer Immunol Immunother. 2006 Jul;55(7):761-74
16187086
Proc Natl Acad Sci U S A. 1989 Jul;86(13):5146-50
2544891
Anticancer Res. 1993 Nov-Dec;13(6A):2207-12
8297135
Blood. 1998 Mar 1;91(5):1706-15
9473237
Blood. 1998 Jan 1;91(1):165-72
9414281
Cancer Immunol Immunother. 1999 Aug;48(5):219-29
10478638
Anticancer Res. 2009 May;29(5):1817-22
19443410
Cancer. 2001 Aug 15;92(4):924-31
11550167
Cancer Immunol Immunother. 2008 Dec;57(12):1891-902
18438664